ERBB2 and inflammatory breast carcinoma: In our larger series, such co‐occurrence was found in 2% of IBC and only 0.2% of non‐IBC, supporting investigation of ERBB3‐inhibitors in combination with ERBB2‐inhibitors in IBC.